Insight Molecular Diagnostics
IMDX
66 hedge funds and large institutions have $63.5M invested in Insight Molecular Diagnostics in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
18% more funds holding
Funds holding: 56 → 66 (+10)
0.25% more ownership
Funds ownership: 2.22% → 2.46% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
6% less capital invested
Capital invested by funds: $67.8M → $63.5M (-$4.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Blackcrane Capital
Bellevue,
Washington
|
+$7.7M |
| 2 |
BC
Broadwood Capital
New York
|
+$2.71M |
| 3 |
BlackRock
New York
|
+$2.67M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$1.05M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$4.99M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$387K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$194K |
| 4 |
Barclays
London,
United Kingdom
|
-$138K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$130K |
IMDX Hedge Fund Activity: Q2 2020 in Review
66 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2020, worth a combined $63.5M — down 6.3% from $67.8M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IMDX positions and 5 closed out — a net gain of 11 holders — while 28 added to existing stakes and 12 trimmed.
The largest buyer was Blackcrane Capital, opening a new position worth an estimated $7.7M. The largest seller was Emerald Mutual Fund Advisers Trust, exiting entirely with an estimated $4.99M sold.
- 66 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2020, up from 56 in Q1 2020.
- Funds reported $63.5M of Insight Molecular Diagnostics stock for Q2 2020, down 6.3% quarter-over-quarter.
- 16 funds opened new Insight Molecular Diagnostics positions in Q2 2020 and 5 closed out, a net change of +11 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2020 was Blackcrane Capital, an estimated $7.7M added.
- The largest Insight Molecular Diagnostics seller in Q2 2020 was Emerald Mutual Fund Advisers Trust, an estimated $4.99M sold.
Based on aggregated 13F filings for Q2 2020.